BRIEF-Keytruda approved in japan for first-line treatment of patients with advanced non-small cell lung cancer
Dec 19 Merck & Co Inc -
* Keytruda (pembrolizumab) approved as first anti-pd-1 therapy in Japan for first-line treatment of patients with advanced non-small cell lung cancer (nsclc) whose tumors express high levels of PD-l1
* Keytruda also approved for second-line treatment of patients with advanced NSCLC whose tumors express PD-l1 Source text for Eikon: Further company coverage:
Kraft withdraws offer to merge with Unilever
UPDATE 3-SpaceX launches rocket from historic NASA pad in Florida
CAPE CANAVERAL, Fla., Feb 19 A SpaceX Falcon rocket blasted off on Sunday from a Florida launch pad once used to send NASA astronauts to the moon, a step forward for billionaire entrepreneur Elon Musk and his company's goal of ferrying astronauts to the International Space Station. The 229-foot tall (70-meter) Falcon 9 soared off a seaside launchpad at the Kennedy Space Center at 9:39 a.m. ET (1439 GMT) carrying a Dragon cargo ship bound for the station.